Scholarlink

Purpose of Review <p>To provide an updated overview of recent advancements in transcatheter solutions for tricuspid regurgitation (TR), focusing on transcatheter edge-to-edge repair (T-TEER) and transcatheter tricuspid valve replacement (TTVR), evaluating their efficacy, safety profiles, and future directions.</p> Recent Findings <p>The TRILUMINATE Pivotal trial showed that T-TEER with the TriClip device significantly reduced TR severity, with 89% of patients achieving ≤ moderate TR at one year, and improved quality of life scores. The TRISCEND II trial demonstrated that TTVR with the EVOQUE system led to 95% of patients achieving TR ≤ mild at one year. However, TTVR was associated with higher procedural risks, including a 10% rate of severe bleeding and a 25% rate of new pacemaker implantation.</p> Summary <p>High-quality evidence from recent randomized trials confirms the benefits of transcatheter tricuspid interventions. T-TEER offers symptomatic improvement with an excellent safety profile, though residual TR may persist. TTVR provides substantial TR reduction but with increased procedural risks. The current risk-benefit profile of these modalities supports T-TEER as a first line approach when feasible. Future research should focus on optimizing patient selection, refining device designs to reduce complications, and conducting long-term studies on hard endpoints such as survival and heart failure hospitalizations to fully assess the impact of these therapies on patient outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Percutaneous Treatment Options for Tricuspid Regurgitation Therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月6日

查看全文
  • Matteo Sturla,
  • Julio Echarte Morales,
  • Andrea Scotti,
  • Pier Pasquale Leone,
  • Juan Torrado,
  • Antonella Millin,
  • Tadahisa Sugiura,
  • Manaf Assafin,
  • Edwin C. Ho,
  • Azeem Latib

摘要

Purpose of Review

To provide an updated overview of recent advancements in transcatheter solutions for tricuspid regurgitation (TR), focusing on transcatheter edge-to-edge repair (T-TEER) and transcatheter tricuspid valve replacement (TTVR), evaluating their efficacy, safety profiles, and future directions.

Recent Findings

The TRILUMINATE Pivotal trial showed that T-TEER with the TriClip device significantly reduced TR severity, with 89% of patients achieving ≤ moderate TR at one year, and improved quality of life scores. The TRISCEND II trial demonstrated that TTVR with the EVOQUE system led to 95% of patients achieving TR ≤ mild at one year. However, TTVR was associated with higher procedural risks, including a 10% rate of severe bleeding and a 25% rate of new pacemaker implantation.

Summary

High-quality evidence from recent randomized trials confirms the benefits of transcatheter tricuspid interventions. T-TEER offers symptomatic improvement with an excellent safety profile, though residual TR may persist. TTVR provides substantial TR reduction but with increased procedural risks. The current risk-benefit profile of these modalities supports T-TEER as a first line approach when feasible. Future research should focus on optimizing patient selection, refining device designs to reduce complications, and conducting long-term studies on hard endpoints such as survival and heart failure hospitalizations to fully assess the impact of these therapies on patient outcomes.